Take note, I-O players. Bristol-Myers to sell Opdivo in China at half-price: report

22nd August 2018 Uncategorised 0

The benchmark for prices of future immuno-oncology therapies in China is here. Bristol-Myers Squibb is pricing its PD-1 star Opdivo, the first cancer immunotherapy approved in China, at half its U.S. cost.

More: Take note, I-O players. Bristol-Myers to sell Opdivo in China at half-price: report
Source: fierce